Table 1.
Characteristics of Australian population aged 65+ overall and according to vaccine doses received at 1 January 2022.
| Mean age (SD) | Unvaccinated (N = 195,138) |
1 dose (N = 36,654) |
2 doses (N = 2,740,926) |
3 doses (N = 893,431) |
4 doses (N = 877) |
Total (N = 3,867,026) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.5 (7.9) |
75.9 (8.5) |
74.2 (7.3) |
75.8 (7.3) |
76.4 (7.5) |
74.6 (7.4) |
|||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |
| Age group (years) | ||||||||||||
| 65–79 | 147,784 | 75.7% | 25,141 | 68.6% | 2,120,660 | 77.4% | 645,879 | 72.3% | 618 | 70.5% | 2,940,082 | 76.0% |
| 80+ | 47,354 | 24.3% | 11,513 | 31.4% | 620,266 | 22.6% | 247,552 | 27.7% | 259 | 29.5% | 926,944 | 24.0% |
| Sexa | ||||||||||||
| Men | 85,108 | 43.6% | 15,630 | 42.6% | 1,276,932 | 46.6% | 422,532 | 47.3% | 479 | 54.6% | 1,800,681 | 46.6% |
| Women | 109,914 | 56.3% | 21,005 | 57.3% | 1,462,692 | 53.4% | 470,591 | 52.7% | 397 | 45.3% | 2,064,599 | 53.4% |
| Weekly household income (AUD) | ||||||||||||
| 0–499 | 63,624 | 32.6% | 11,174 | 30.5% | 762,630 | 27.8% | 185,864 | 20.8% | 172 | 19.6% | 1,023,464 | 26.5% |
| 500–999 | 64,793 | 33.2% | 11,553 | 31.5% | 958,656 | 35.0% | 292,699 | 32.8% | 258 | 29.4% | 1,327,959 | 34.3% |
| 1000–1499 | 20,473 | 10.5% | 3640 | 9.9% | 363,170 | 13.2% | 123,761 | 13.9% | 129 | 14.7% | 511,173 | 13.2% |
| 1500–1999 | 7916 | 4.1% | 1487 | 4.1% | 164,376 | 6.0% | 62,957 | 7.0% | 55 | 6.3% | 236,791 | 6.1% |
| 2000+ | 6452 | 3.3% | 1203 | 3.3% | 157,608 | 5.8% | 83,639 | 9.4% | 100 | 11.4% | 249,002 | 6.4% |
| Other (incl not stated) | 31,885 | 16.3% | 7601 | 20.7% | 334,491 | 12.2% | 144,515 | 16.2% | 163 | 18.6% | 518,655 | 13.4% |
| State of residencea | ||||||||||||
| New South Wales | 53,961 | 27.7% | 6115 | 16.7% | 889,576 | 32.5% | 303,876 | 34.0% | 362 | 41.3% | 1,253,890 | 32.4% |
| Victoria | 40,229 | 20.6% | 5756 | 15.7% | 703,405 | 25.7% | 221,595 | 24.8% | 231 | 26.3% | 971,216 | 25.1% |
| Queensland | 49,776 | 25.5% | 9742 | 26.6% | 518,287 | 18.9% | 189,368 | 21.2% | 135 | 15.4% | 767,308 | 19.8% |
| South Australia | 17,717 | 9.1% | 5032 | 13.7% | 228,814 | 8.3% | 66,160 | 7.4% | 70 | 8.0% | 317,793 | 8.2% |
| Western Australia | 25,966 | 13.3% | 8107 | 22.1% | 281,699 | 10.3% | 64,458 | 7.2% | 53 | 6.0% | 380,283 | 9.8% |
| Tasmania | 4743 | 2.4% | 1457 | 4.0% | 71,216 | 2.6% | 24,848 | 2.8% | 17 | 1.9% | 102,281 | 2.6% |
| Australian Capital Territory | 1546 | 0.8% | 250 | 0.7% | 36,973 | 1.3% | 18,651 | 2.1% | 13 | 1.5% | 57,433 | 1.5% |
| Northern Territory | 1177 | 0.6% | 198 | 0.4% | 10,631 | 0.4% | 4412 | 0.5% | 5 | 0.6% | 16,423 | 0.4% |
| No. of comorbiditiesb | ||||||||||||
| 0 | 50,066 | 25.7% | 4488 | 12.2% | 249,397 | 9.1% | 50,237 | 5.6% | 55 | 6.3% | 354,243 | 9.2% |
| 1 | 28,265 | 14.5% | 3810 | 10.4% | 314,684 | 11.5% | 81,884 | 9.2% | 77 | 8.8% | 428,720 | 11.1% |
| 2 | 26,653 | 13.7% | 4541 | 12.4% | 403,206 | 14.7% | 118,049 | 13.2% | 98 | 11.2% | 552,547 | 14.3% |
| 3+ | 90,154 | 46.2% | 23,816 | 65.0% | 17,73,640 | 64.7% | 643,266 | 72.0% | 655 | 74.7% | 2,531,531 | 65.5% |
| No. of GP visits in year prior | ||||||||||||
| 0 | 29,217 | 15.0% | 2422 | 6.6% | 94,832 | 3.5% | 24,130 | 2.7% | 34 | 3.9% | 150,635 | 3.9% |
| 1–2 | 23,826 | 12.2% | 3079 | 8.4% | 184,787 | 6.7% | 38,973 | 4.4% | 45 | 5.1% | 250,710 | 6.5% |
| 3–6 | 50,087 | 25.7% | 8132 | 22.2% | 725,127 | 26.5% | 193,236 | 21.6% | 149 | 17.0% | 976,731 | 25.3% |
| 7–12 | 46,365 | 23.8% | 9780 | 26.7% | 906,595 | 33.1% | 301,453 | 33.7% | 299 | 34.1% | 1,264,492 | 32.7% |
| 13+ | 45,645 | 23.4% | 13,246 | 36.1% | 829,587 | 30.3% | 335,636 | 37.6% | 359 | 40.9% | 1,224,473 | 31.7% |
| Influenza vaccine in 2021 | 35,139 | 18.0% | 14,918 | 40.7% | 1,972,934 | 72.0% | 762,768 | 85.4% | 739 | 84.3% | 2,786,498 | 72.1% |
| In residential aged care facility | 7404 | 3.8% | 3429 | 9.4% | 52,012 | 1.9% | 64,961 | 7.3% | 77 | 8.8% | 127,883 | 3.3% |
| COVID-19 vaccine primary doses branda | ||||||||||||
| Pfizer (BNT162b2) | 16,657 | 45.4% | 340,014 | 12.4% | 128,655 | 14.4% | 192 | 21.9% | 485,518 | 12.6% | ||
| Astra Zeneca (ChAdOx1) | 15,689 | 42.8% | 2,353,786 | 85.9% | 764,560 | 85.6% | 682 | 77.8% | 3,134,717 | 81.1% | ||
| Moderna (mRNA-1273) | 4236 | 11.6% | 45,478 | 1.7% | 43 | 0.0% | 0 | 0.0% | 49,757 | 1.3% | ||
| Mean number of weeks since receipt of most recent dose (SD) | 9.1 (9.2) | 16.5 (6.1) | 2.2 (2.3) | 3.3 (4.1) | ||||||||
All numbers were perturbed to maintain confidentiality. See methods for details.
a
For COVID-19 vaccine primary doses the % is of all those receiving that dose but for the overall population it includes the unvaccinated.
b
See methods for how co-morbid conditions were determined.